NOVOCART 3D is part of a U.S. Food and Drug Administration Investigational New Drug Phase 3 randomized, multicenter study. The product is a matrix-induced autologous chondrocyte product, designed to repair articular cartilage defects of the knee.
Kenneth R. Zaslav, MD, an orthopedic surgeon with Advanced Orthopedics in Richmond, Va., performed the implantation during a knee surgery.
Aesculap Biologics, a division of Aesculap, is focused on biological approaches for the repair and regeneration of diseased or damaged tissues.
More articles on devices:
8 things to know about the Asia-Pacific minimally invasive spine device market
15 spine devices receive FDA 510(k) clearance in August
Former ArthroCare execs get 10+ years in prison for fraud costing shareholders $750M
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
